(Ln - Milano) Lombardy Region has undertaken concrete actions and effective and will continue to strive for Nerviano Medical Sciences because "the Center continues to be among the largest pharmaceutical research and development centers in Italy and one of the major poles of integrated identification and development of cancer drugs in Europe. "He reiterated this morning the President of the Lombardy Region in a speech today at the round table, organized by Nerviano Medical Sciences and Farmindustria to" cancer research and clinical trials: a comparison competitive and international collaboration. "
NERVIANO AND ROL - The President recalled the adoption by the Regional Council last December of a three-year project from 15 million to promote an agreement between the network of pre-clinical and clinical research of the Network Oncology Lombarda (ROL) and Nerviano Medical Sciences through research, coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori, dedicated development of biomarkers and anti-tumor drugs.
"The ultimate goal of this agreement - said the president - is to transfer the innovation in new methods of prevention, new diagnostic tools and earlier in the development of new drugs." Through this alliance is thus the possibility of obtaining a double benefit: it is a manufacturing firm as that of Nerviano to a reality of pre-clinical and clinical research that allows you to practice and develop the best possible production research and knowledge, you have the opportunity to test new cancer drugs in an appropriate manner, or by a model called "translational", which assumes tight integration with a continuous exchange of information between laboratory and clinical activity, important in order to transfer quickly to the bedside the results of the research.
personalized medicine - The President has indicated in the personalization of medicine of the future direction of medical science. "This area - said - is very strategic because the results will be achieved that will foster personalized medicine, drug therapy, reducing the risk of undesirable reactions to medicines in the world is still the fourth leading cause of death."
"What we imagine - said the president - is that in future people can have a "health card", which is necessary to prescribe medication. All this becomes even more urgent in terms of economic management: the region's health spending is the real test of the efficient management of resources and have 'drug ad personam' will reduce the overall cost of disease, thereby reducing hospitalization.
RESEARCH AND COMPETITIVENESS - According to the president, "this field of research and application is also a real opportunity to boost our competitiveness." Lombardy is the first chemical-pharmaceutical and biotech region in Italy, with more than 100 pharmaceutical companies and 58.5% of clinical trials compared to the national total.
Lombardy, in 2008, has invested in this sector of € 2.5 billion, of which almost 700 million for the acquisition of innovative high-cost medicines in hospitals (cancer drugs, drugs for rare diseases, drugs for HIV patients). Since 2006 the Lombardy expected - the first region in Italy - reimbursement of innovative cancer therapies. In addition, under the new rules, 2010, the Region has decided on a further 10% increase on the budget for purchases by hospitals in high-cost drugs.
From: Lombardia News
0 comments:
Post a Comment